• Shuffle
    Toggle On
    Toggle Off
  • Alphabetize
    Toggle On
    Toggle Off
  • Front First
    Toggle On
    Toggle Off
  • Both Sides
    Toggle On
    Toggle Off
  • Read
    Toggle On
    Toggle Off
Reading...
Front

Card Range To Study

through

image

Play button

image

Play button

image

Progress

1/22

Click to flip

Use LEFT and RIGHT arrow keys to navigate between flashcards;

Use UP and DOWN arrow keys to flip the card;

H to show hint;

A reads text to speech;

22 Cards in this Set

  • Front
  • Back
3 myelodysplastic syndromes
preleukemia
subacute leukemia
dysmyelopoietic syndrome
median age of MDS onset
70
MDS presents with
moderate/severe anemia
MDS disease course is usually
indolent
MDS is usually ___ but can be ___
idiopathic
heredofamilial
secondary MDS is more/less aggressive than primary and has more/less cytogenetic abnormalities
more
more
in MDS there's ___penia
pancyto
to diagnose MDS you need to exclude
B12/folate deficiency
heavy metal exposure
cytotoxic tx
inflammation
3 aspects of abnormal maturation in MDS
abnormal response to GFs
erthropoiesis inhibition by cytokines
increased apoptosis
4 cytokines driving apoptosis in MDS
TNF
IFNg
IL1
TGFb
leukemic tendency in MDS is associated with ___
karyotypic abnormalities
3 cytogenetic abnormalities associated with good prognosis
Y-
5q-
20q-
1 cytogenetic abnormality associated with bad prognosis
7
5 MDS subtypes
reactive anemia (RA)
RA with ringed sideroblasts (RARS)
RA with excessive blasts (RAEB)
RAEB with leukemic transformation (RAEB-t)
chronic myelo monocytic leukemia (CMML)
2 MDS subtypes with low risk of transformation
RA
RARS
3 MDS prognostic factors
age
platelet count
BM blasts %
in 5q del syndrome megakaryocytes are ___
hyposegmented
CMML occurs after age ___. ___ are visible in PB and ___ in BM.
50
myelocytes
monocytic hyperplasia
tx for low-risk MDS
supportive tx
GFs
immune modulation
Fe chelation
GFs given for MDS
EPO
G-CSF
drugs given for low-risk MDS
linelidomide
azacitidine
tx for high-risk MDS
supportive
chemo
stem cell transplant
BMT